Pearl Therapeutics, Inc.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Pearl Therapeutics, Inc.
Front panels for 34 SKUs for Haleon’s Nicorette 2- and 4-mg gum in approved to include a superimposed letter N; labeling approved for seven SKUs for Kenvue’s Zyrtec Allergy 5- and 10-mg tablets to include “new” for six months.
Futura Medical has extended its licensing agreement with Cooper Consumer Health for the rights to market its Eroxon topical, gel-based erectile dysfunction treatment throughout the European Economic Area, United Kingdom and Switzerland until 2029.
Plus deals involving AstraZeneca/Allorion, Concentra/Theseus, Janssen/MeiraGTx, Lilly/Fauna and more.
The largest shareholder in major Japanese pharma firm Taisho, the founding Uehara family, intends to smooth the way to the restructuring and expansion of the business by acquiring and delisting all of its stock. The nearly $5bn size of the deal would makes it the biggest management buyout in Japanese corporate history.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.